banner
LightNews
hcplivenews.bsky.social
HCPLive
@hcplivenews.bsky.social
70 followers 72 following 800 posts
Everything you need to enhance your approach to improving patient care.
Posts Media Videos Starter Packs
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 41m
A new trial found that an educational intervention boosted pediatricians’ adherence to early peanut introduction guidelines, rising to 83.7% for low-risk infants. www.hcplive.com/view... #PeanutAllergy #FoodAllergy #Allergy
New Intervention Boosts Early Peanut Introduction to Prevent Peanut Allergy | HCPLive
A new trial reveals that educational interventions significantly enhance pediatricians' adherence to guidelines for early peanut introduction.
www.hcplive.com
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 4h
During #HFSA2025, we sat down with Barry Borlaug, MD, to discuss his prespecified analysis of sex differences with tirzepatide for obesity-related heart failure, based on results from the phase 3 SUMMIT trial.

Watch now:
Tirzepatide Affects Men and Women with HFpEF Equally, With Barry Borlaug, MD | HCPLive
A prespecified secondary analysis revealed no difference in male and female patients’ responses to tirzepatide in obesity-related HFpEF.
www.hcplive.com
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 6h
Taladegib was safe and demonstrated promising efficacy in a phase 2a trial in people with idiopathic pulmonary fibrosis (IPF). Read more:
Taladegib Shows Potential to Improve FVC in Idiopathic Pulmonary Fibrosis | HCPLive
The therapy was well-tolerated in the phase 2a ENV-IPF-101 trial, with mostly mild-to-moderate TEAEs related to treatment.
www.hcplive.com
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 8h
New research suggests high intake of both sugar-sweetened beverages and low- or non-sugar-sweetened beverages incurs an increased MASLD risk, encouraging limiting their intake as part of a prevention strategy for liver disease and cardio-renal-metabolic health.

Read more:
Sugar-, Artificially-Sweetened Beverages Both Linked to Increased MASLD Risk | HCPLive
High intake of both sugar-sweetened beverages and low- or non-sugar-sweetened beverages was linked to greater MASLD risk.
www.hcplive.com
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 17h
New research links small intestinal dilation to severe abdominal symptoms in adults with #FPIES. An 8-question evaluation algorithm may help clinicians assess abdominal distension in these patients.
Small Intestine Dilation Links to Food-Protein-Induced Enterocolitis Syndrome | HCPLive
A recent study reveals that small intestinal dilation significantly contributes to abdominal symptoms in adults with Food-Protein-Induced Enterocolitis Syndrome (FPIES).
www.hcplive.com
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 21h
ICYMI: Following the #FDA approval of roflumilast cream for #AtopicDermatitis, HCPLive spoke with Lawrence Eichenfield, MD, about his team’s findings on the drug and its efficacy.

View: www.hcplive.com/view/signifi...
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 1d
Poor blood glucose control in children with type 1 diabetes may lead to increased risk of neuropathy in adulthood, according to new research from the University of Michigan.

Read more: www.hcplive.com/view...
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 1d
New research is shedding light on increases in short-term kidney function decline following post-COVID-19 vaccination gross hematuria in individuals with IgA nephropathy.

Learn more: www.hcplive.com/view...
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 1d
A new study suggests subcutaneous administration of methotrexate (MTX) for #psoriasis, as opposed to oral administration, may enhance the effectiveness of this drug in patients but also increase their risk of adverse effects.💡

Want to know more?

🔗View: www.hcplive.com/view...
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 1d
In a new study, an educational intervention boosted pediatricians’ adherence to early peanut introduction guidelines, rising to 83.7% for low-risk infants. www.hcplive.com/view...
#PeanutAllergy
New Intervention Boosts Early Peanut Introduction to Prevent Peanut Allergy | HCPLive
A new trial reveals that educational interventions significantly enhance pediatricians' adherence to guidelines for early peanut introduction.
www.hcplive.com
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 1d
Anju Peters, MD, director of Clinical Research in the Division of Allergy and Immunology at Northwestern University Feinberg School of Medicine, discussed the significance of comparing dupilumab and omalizumab and what the results mean for managing CRSwNP.

Watch now: www.hcplive.com/view/dupilum...
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 2d
Come catch up on the most important #ophthalmology news from the third quarter of 2025 with our Q3 recap, collecting FDA approvals, trial updates, and more!

Read now: www.hcplive.com/view...
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 2d
In EVEREST, dupilimab was superior to omalizumab in patients with severe, uncontrolled CRSwNP, although both biologics were well-tolerated and efficacious. Hear more from Anju Peters, MD @northwesternmed now: www.hcplive.com/view...
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 2d
Following the #FDA approval of roflumilast cream for #AtopicDermatitis, HCPLive spoke with Lawrence Eichenfield, MD, about his team’s findings on the drug and its efficacy.

View:
Significance of Roflumilast Approval for Atopic Dermatitis in Children, With Lawrence Eichenfield, MD | HCPLive
This interview follows the FDA’s recent approval of Arcutis's roflumilast (Zoryve) cream 0.05% for patients aged 2-5 years with atopic dermatitis.
www.hcplive.com
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 2d
Following FDA approval, #donidalorsen (Dawnzera) shows strong efficacy and safety in patients switching from other #HAE prophylactic therapies.
William Lumry, MD, discusses pivotal switch data and real-world impact: www.hcplive.com/view/switchi...
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 3d
From FDA decisions to key trial data, we've collected the most crucial headlines in cardiology from the last 3 months: catch up on what you missed with our Q3 2025 recap!

Read now: www.hcplive.com/view...
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 3d
New data from the LUCENT-3 open-label extension study establish mirikizumab (Omvoh) as the first and only IL-23p19 to help patients with moderately to severely active ulcerative colitis achieve sustained, long-term outcomes through 4 years.

Read more: www.hcplive.com/view...
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 3d
In a new study, secukinumab and ixekizumab had similar clinical efficacy in treating moderate-to-severe #psoriasis, but secukinumab was shown to offer superior psychological benefits.

View here: www.hcplive.com/view...
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 3d
The FDA has approved donidalorsen (Dawnzera)—the first RNA-targeted therapy for hereditary angioedema (HAE).
In an interview with Dr. William Lumry, he discusses how targeting prekallikrein opens a new path in HAE prevention.
www.hcplive.com/view...
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 3d
We spoke with Vimal H. Prajapati, MD, from @University of Calgary about the new FDA approval of guselkumab for pediatric psoriasis and psoriatic arthritis. Learn more about how the new approval's impact in the field now:
www.hcplive.com/view/bridgin...
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 4d
Come catch up on some of the most important #cardiology news with our Month in Review! From FDA approvals to professional insights, we've collected some unmissable headlines from September 2025.

Read now: www.hcplive.com/view...
1
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 4d
Today, the FDA approved roflumilast (Zoryve) cream 0.05% for the topical treatment of mild to moderate atopic dermatitis in children 2-5 years of age, marking the 6th FDA approval for the PDE4 inhibitor’s portfolio in just over 3 years.

Learn more: www.hcplive.com/view...
1
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 4d
NEW: In a phase 2 proof-of-concept trial, treatment with topical bimiralisib gel 2% has achieved high rates of #ActinicKeratosis lesion clearance and has been well tolerated in patients with this condition.

View here:
Topical Bimiralisib Shows 92% Clearance Rate for Patients with Actinic Keratosis | HCPLive
These new, phase 2 findings on the use of topical bimiralisib suggest positive results among patients with actinic keratosis.
www.hcplive.com
1
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 6d
New research has shown that over 99% of patients who experience heart attacks, strokes, and heart failures had cardiovascular risk factors present prior, overturning a common misconception.

Read now:
99% of Heart Attacks, Strokes, Heart Failures Have Cardiovascular Risk Factors Beforehand | HCPLive
Recent research refutes the conception that most, if not all, coronary heart disease occurs without typical CVD risk factors.
www.hcplive.com
hcplivenews.bsky.social
HCPLive @hcplivenews.bsky.social · 6d
HCPLive has provided a review highlighting some of the most notable news coverage from the months of July, August, and September in #dermatology.

View:
Q3 2025 Recap: Dermatology News and Updates | HCPLive
This review of Q3 developments in the dermatology space highlight a number of significant news stories from 2025.
www.hcplive.com